Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27280782 | 1.00 | MAPT (0.60) | MAPTPOLBLMNASMN1; SMN2KMT2A | |
| SCHEMBL21827346 | 1.00 | MAPT (0.60) | MAPTPOLBLMNASMN1; SMN2KMT2A | |
| SCHEMBL24391219 | 0.79 | MAPT (0.47) | MAPTPOLBLMNASMN1; SMN2KMT2A | |
| SCHEMBL24391158 | 0.79 | MAPT (0.47) | MAPTPOLBLMNASMN1; SMN2KMT2A | |
| SCHEMBL11623232 | 0.79 | APEX1 (0.46) | MAPTPOLBLMNASMN1; SMN2KMT2A | |
| SCHEMBL13189754 | 0.77 | MAPT (0.46) | MAPTPOLBLMNASMN1; SMN2KMT2A | |
| SCHEMBL26075213 | 0.76 | MAPT (0.57) | MAPTPOLBLMNASMN1; SMN2KMT2A | |
| SCHEMBL19262494 | 0.76 | MAPT (0.57) | MAPTPOLBLMNASMN1; SMN2KMT2A | |
| SCHEMBL3751829 | 0.76 | MAPT (0.57) | MAPTPOLBLMNASMN1; SMN2KMT2A | |
| SCHEMBL25227301 | 0.75 | MAPT (1.00) | MAPTPOLBLMNASMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270222-A1 | AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF | SATELLOS BIOSCIENCE INC. (CA) | 2025-08-28 | — | — | US | disclosed |
| US-20250122207-A1 | AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF | SATELLOS BIOSCIENCE INC. (CA) | 2025-04-17 | — | — | US | disclosed |
| WO-2025054448-A1 | AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF | SATELLOS BIOSCIENCE INC. (CA) | 2025-03-13 | — | — | WO | disclosed |
| WO-2024081311-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| US-20230303494-A1 | BENZYLAMINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | ACADEMY OF MILITARY MEDICAL SCIENCES (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230303494-A1 | BENZYLAMINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | ACADEMY OF MILITARY MEDICAL SCIENCES (CN) | 2023-09-28 | — | — | US | disclosed |
| EP-4198017-A1 | BENZYLAMINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | Academy of Military Medical Sciences (CN) | 2023-06-21 | — | — | EP | disclosed |
| US-20220135542-A1 | 1-((S)-1-(3-CHLORO-5-FLUORO-2-((4-(1H-PYRAZOL-1-YL)-2-METHYLQUINOLIN-8-YLOXY)METHYL)PHENYL)ETHYL)-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ (BK) B2 RECEPTOR ANTAGONIST FOR TREATING SKIN DISEASES | PHARVARIS GMBH (CH) | 2022-05-05 | — | — | US | disclosed |
| WO-2022033303-A1 | BENZYLAMINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 中国人民解放军军事科学院军事医学研究院 | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122207-A1 | AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF | AAK1, CAMKK1, AP2A1 | MAPT 1810/4885POLB 3694/4885LMNA 2115/4885 |
| US-20230303494-A1 | BENZYLAMINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | CD274, PDCD1, PDCD1LG2 | MAPT 2862/4885POLB 3163/4885LMNA 2409/4885 |
| US-20250270222-A1 | AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF | AAK1, AP2A1, CSNK1A1 | MAPT 1885/4885POLB 3869/4885LMNA 3437/4885 |
| US-20220135542-A1 | 1-((S)-1-(3-CHLORO-5-FLUORO-2-((4-(1H-PYRAZOL-1-YL)-2-METHYLQUINOLIN-8-YLOXY)METHYL)PHENYL)ETHYL)-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ (BK) B2 RECEPTOR ANTAGONIST FOR TREATING SKIN DISEASES | BDKRB2, BDKRB1, BRCA1 | MAPT 4290/4885POLB 3332/4885LMNA 3241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.